Original language | English |
---|---|
Publisher | National Institute for Health and Care Excellence |
Commissioning body | NICE Decision Support Unit |
Publication status | Published - 2016 |
Cancer Drugs Fund rapid review of dasatinib for treating imatinib-resistant chronic myeloid leukaemia and for people for whom treatment with imatinib has failed because of intolerance (part review of NICE Guidance TA 241) and dasatinib for the first-line treatment of chronic myeloid leukaemia (part review of NICE Guidance TA 251). Decision Support Unit Report for the National Institute for Health and Care Excellence
Research output: Book/Report › Commissioned report